CureVac N.V. CVAC 深 沪
等待开盘 11-26 09:30:00 美东时间
5.28
+0.170
+3.33%
华盛通- 最 高5.29
- 今 开5.11
- 成交量 192.26万股
- 最 低 5.07
- 昨 收 5.11
- 总市值 11.88亿
- 52周最高 5.72
- 市盈率 静 6.75
- 换手率 0.85%
- 52周最低 2.475
- 委 比 57.99%
- 总股本 2.25亿
- 历史最高 151.80
- 量 比 1.78
- 振 幅 4.31%
- 历史最低 2.215
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate
CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same
11-24 21:18
CureVac GAAP EPS of €1.21, revenue of €54.13M
CureVac BV press release (CVAC): Q3 GAAP EPS of €1.21. Revenue of €54.13M (-89.0% Y/Y). Strong cash and cash equivalents position of €416.1 million as of September 30, 2025, confirming expected cash r...
11-24 20:46
BioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share
Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology
10-22 18:51
BioNTech杀疯了
（来源：药剂Talks） mRNA疫苗巨头BioNTech正在狂奔。 6月2日，百时美施贵宝（BMS）宣布就PD-L1/VEGF双抗BNT327（普米斯生物的...
09-12 09:15
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
09-05 21:09
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Sciences, Inc. announced that its CEO, Rick Barry, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8, 2025. The event will feature a corporate presentation at 5 PM ET, available via webcast and replay on Cassava's investor website for 90 days. Cassava, a biotechnology company focused on CNS disorder treatments, is based in Austin, Texas.
08-25 12:00
CureVac Reports Financial Losses in Mid-2025
CureVac ( ($CVAC) ) has issued an update. CureVac N.V. released its unaudited i...
08-16 04:43
CureVac Reports Q2 Revenues Of EUR1.2M, Lower Than EUR14.4M YoY
The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licensing Agreement as well as lower sales to CRISPR
08-15 19:58
BioNTech Settles Patent Disputes with CureVac and GSK
BioNTech SE ( ($BNTX) ) has provided an update. On August 7, 2025, BioNTech SE,...
08-11 18:43
